Abstract:Objective. To investigate the feasibility of pre- and postoperative gemcitabine-plus-cisplatin (GC) adjuvant chemotherapy for the treatment of locally advanced urothelial carcinoma in kidney transplant patients. Methods. Seven kidney transplant patients diagnosed with locally advanced urothelial carcinoma were treated with a pre- and postoperative GC adjuvant chemotherapy between January 2008 and March 2012. Gemcitabine (800 mg/m(2)) was administered at as an intravenous infusion on days 1 and 8. A total cisplatin dosage of 100 mg/cycle was administered on 2 days (50 mg/d on days 2 and 3) as an intravenous infusion. A single treatment cycle lasted 21 days. At the beginning of chemotherapy, the cyclosporine (CSA) dosage was reduced by 25 mg/d (on day 1 through day 8) if the blood CSA concentration was well maintained and did not fluctuate significantly. In addition, mycophenolate mofetil was reduced by 500 mg/d, while azathioprine was reduced by 25 mg/d (on day 1 through day 16). One cycle of GC neoadjuvant chemotherapy was given before operation, and several GC cycles were given after operation according to the patients' situation. Retrospective analysis was performed on the clinical data, chemotherapy regimen, chemotherapy efficacy, and side effects of the 7 patients. Results. The 7 patients were all treated with 1 course of presurgical chemotherapy. The seven patients completed 24 treatment cycles of chemotherapy in total. The average GC medication period per patient was 3.4 cycles. The postsurgery follow-up was 6 to 36 months (average-22.1); all of the patients survived. There was 1 case of complete remission (14.5%), 2 of partial remission (28.5%), and 4 of stable disease (57%), with one case of T4N1M0 and three cases of T3N0M0. The overall efficacy was 43%. The toxicity and side effects associated with the GC regimen were largely associated with myelosuppression. The other side effects included reversible nephrotoxicity, gastrointestinal tract and skin reactions, as well as phlebitis. Hematologic toxic reactions included reversible leukopenia, thrombocytopenia, and anemia. There was 1 case of degree III anemia and 1 case of degree II; 5 cases of degree III and 1 of degree II leukopenia; and 3 of degree II thrombocytopenia. Gastrointestinal reactions included nausea, vomiting, and constipation. There were 2 cases of degree III and 4 cases of degree II nausea and vomiting as well as 2 cases of degree III and 3 cases of degree II constipation. There were 3 cases of degree I phlebitis (43%) and 2 cases of degree I skin erythema. The nephrotoxicity reactions were all reversible. Both liver function and grafted kidney function were not significantly altered after chemotherapy compared with prior to chemotherapy. None of the patients suffered renal allograft rejection after chemotherapy; none required additional antirejection drug treatments. The original antirejection treatment regimen was restored after the patients completed the chemotherapy treatment cycles. Conclusion. We confirmed the efficacy of applying a GC regimen to treat locally advanced urothelial carcinoma in kidney transplant patients. The side effects were tolerable and reversible with minor impacts on graft function.

Effect of Combined Treatment with Gemcitabine and Oxaliplatin on Advanced or Metastatic Urothelial Carcinoma

Clinical out comes and safety of gemcitabine combined with oxaliplatin in treatment of urothelial tumor

A Meta-Analysis of Gemcitabine Containing Chemotherapy for Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Study of short-term efficacy of gemcitabine plus cisplatin in treating advanced urothelial carcinoma

Curative Effect of Gemcitabine Combined with Platinum Drugs on Treatment of Advanced Squamous Carcinoma and Adenocarcinoma of Lung

Clinical Research for Gemcitabine Combined with Fluorouracil in the Treatment of Advanced Ovarian Cancer Patients with Taxane and Cisplatin Resistance

The efficacy and toxicity of gemcitabine combined with cisplatin for advanced bladder cancer

A Phase II Trial of Gemcitabine Plus Carboplatin in Advanced Transitional Cell Carcinoma of the Urothelium

Efficacy and safety of transcatheter arterial chemoembolization combined with systemic chemotherapy in urothelial carcinoma patients with liver metastasis

Observation of the Short-term Efficacy of Gemcitabine,Paclitaxel plus Cisplatin in the Treatment of Advanced Urothelial Carcinoma

Gemcitabine and Ifosfamide As a Second-Line Treatment for Cisplatin-Refractory Metastatic Urothelial Carcinoma: a Phase II Study

Efficacy of Oxaliplatin Combined with Pirarubicin and 5-Fluorouracil for Advanced Hepatocellular Carcinoma

Effectiveness of Capecitabine with or Without Docetaxel Therapy for the Treatment of Patients with Advanced Urothelial Carcinoma: a Single-Institution Experience.

The therapeutic effect of gemcitabine combined with cisplatin in advanced liver cancer

The effect of Gemcitabine combined Capecitabine regimens for anthracycline-and taxane-refractory metastatic breast cancer

Feasibility of Pre- and Postoperative Gemcitabine-plus-Cisplatin Systemic Chemotherapy for the Treatment of Locally Advanced Urothelial Carcinoma in Kidney Transplant Patients

Efficacy and Safety of Gemcitabine-Oxaliplatin Combined with Huachansu in Patients with Advanced Gallbladder Carcinoma

[Short-Term Efficacy of Combined Chemotherapy of Gemcitabine and Cisplatin on Advanced Hormone Refractory Prostate Cancer].

Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: an Updated Network Meta-Analysis

Effect of Recombinant Human Endostatin on Antitumor Efficacy of Paclitaxel/Gemcitabine/Cisplatin (tgp) Chemotherapy in the Treatment of Advanced Urothelial Carcinoma

Gemcitabine Plus Oxaliplatin Combination in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer